Drug Approval | January 14, 2026
Camurus’ Oclaiz NDA resubmission accepted by FDA
The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 10, 2026
The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 10, 2026
Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity
The cancellation underscores the regulator’s strict stance against misleading cosmetic claims
Adverse events were consistent with valbenazine’s established safety profile
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development
Deceased donor kidney transplants are time-critical, and it is uncommon to attempt them robotically
ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia
This innovation reinforces Fredun's commitment to creating a 360 degree pet wellness ecosystem
Early stage projects of up to Rs. 9 crore eligible for up to Rs. 5 crore assistance and later stage projects of up to Rs. 285 crore eligible for up to Rs. 100 crore assistance
Subscribe To Our Newsletter & Stay Updated
